Beyondspring

Beyondspring company information, Employees & Contact Information

Explore related pages

Related company profiles:

BeyondSpring Pharmaceuticals is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes. The Company is developing treatments in two of the world’s largest markets, China and the United States. BeyondSpring’s first-in-class lead asset plinabulin, a selective immunomodulating microtubule-binding agent, is being developed as a “pipeline in a drug” with potential to be an anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). In the DUBLIN-3 Phase 3 study, the plinabulin and docetaxel combination met the primary endpoint of extending overall survival, compared to docetaxel alone in 2nd/3rd line non-small cell lung cancer (EGFR wild type). In addition, the plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data, for which it received Breakthrough status in the U.S. and China. Plinabulin is also currently being studied as part of other immuno-oncology (IO) combination regimens that include radiation and/or checkpoint inhibitors for the treatment of a number of cancers. Lastly, BeyondSpring also has three preclinical IO assets and majority ownership in its subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Company Details

Employees
50
Address
28 Liberty Street, New York,ny 10005,united States
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
New York, NY
Looking for a particular Beyondspring employee's phone or email?

Beyondspring Questions

News

BeyondSpring Announces $35.4 Million Sale of a Portion of - GlobeNewswire

BeyondSpring Announces $35.4 Million Sale of a Portion of GlobeNewswire

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update Yahoo Finance

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors - Stock Titan

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Stock Titan

BeyondSpring Reports Second‑Quarter 2025 Financial Results - GlobeNewswire

BeyondSpring Reports Second‑Quarter 2025 Financial Results GlobeNewswire

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - Yahoo Finance

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors Yahoo Finance

SEED Therapeutics (SEED) Enters into Strategic Research - GlobeNewswire

SEED Therapeutics (SEED) Enters into Strategic Research GlobeNewswire

BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly - GlobeNewswire

BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly GlobeNewswire

Top Beyondspring Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant